Background: The RV144 trial showed promise towards the development of an effective HIV vaccine, Antibodies to HIV Env VIV2 loop, Env-specific IgA and HLA class II DQBL*06 allele with high Env IgA were all significantly associated with risk of infection. Methods: We used an integrated systems biology approach to identify novel correlates of immunogenicity and/or protection. Env-specific stimulated peripheral blood mononuclear cells from RV144 participants were used to test the hypothesis that innate pro-inflammatory responses would demarcate RVl44 case-control groups. Results: A case/control gene expression analysis using 133 controls and 27 cases yielded few significantly differentially expressed genes between cases and controls, To adjust for the heterogeneity and the case/control class imbalance, we employed a stratification strategy using a tree-based classification method with IgA, V!V2 and DQB1*06 as predictor variables and the infection status as the outcome. The obtained tree model showed a balanced accuracy of 61 % and identified two different risk groups. Cases in the first group had low IgA titers and did not express the DQB 1 *06 allele. Transcriptional profiling showed downregulation of the type ll interferon induced genes (Fisher enrichment test p value "" 0.04) in these cases compared to controls. Cases in the second Group had high IgA and Low VIV2 titers, Transcriptional profiling showed, interestingly, upregulution of several type I interferon genes including antiviral genes (Fisher enrichment test p value = 10-6 ) in these cases compared to controls. Conclusions: Herein we have identified a gene expression signature, segregating case and control donors and which, counterintuitively, shows contrasting roles for innate immune response genes in conferring vaccine induced protection. These results have important implications for the development of more effective HIV vaccine strategies. Background: Understanding molecular mechanisms of natural disease control in the absence of treatment in a minor group of HIV-infected subjects, identified as slow progressors (SP), represents a logical approach towards a potential functional cure.
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OA04. Background: Understanding molecular mechanisms of natural disease control in the absence of treatment in a minor group of HIV-infected subjects, identified as slow progressors (SP), represents a logical approach towards a potential functional cure.
Methods: In the current study we aimed to identify molecular signatures associated with viral control in our Canadian cohort of HIV-infected SP (Study # CTN 247; subjects maintaining CD4 counts over 500/microliter for over 7 years, in the absence of treatment). To this end, we have identified 5 subjects that have experienced a sudden loss of viral control (average increase of viral load: 5 to 79 fold) and a decline in the absolute CD4 counts (average loss: 211 cells/microliter). We used the Illumina technology to study genome-wide transcriptional profiles in peripheral blood mononucleated cells {PBMCs) isolated from these subjects before (Visit l) and after (Visit 2) the loss of virological control. Rl'sults: Our analysis identified 1,381 probe sets corresponding to 1,268 genes that were differentially expressed between VI and V2 (nominal p-value<5%). Among these genes, 864 were downregulated and 517 were upregulated at V2 versus VI. Of note, among the down-regulated genes, several members of both innate and adaptive anti-viral responses were identified such as APOBEC3G, IL-32, the T cell receptor CD96 (known to associated with the superior quality of CD& T cells in HIVit1fected Elite controllers), Lek, LAT, JAKl, ITK and the IL-7 receptor (IL-7R). Our validation assays are currently in progress to validate the expression of these genes at the protein level. Conclusions: Our current study takes advantage of the power of the whole genome transcriptional analysis on privileged samples from HIV-infected SP subjects before and after the Joss of virological control to identify new targets for therapeutic interventions and also to identify early biomarkers to predict disease progression.
Vaccine, Viral Latency, and Cure - Background: Recent reports in humanized mice and monkeys have found that broadly neutralizing antibodies (bNAbs) can suppress the replication of laboratory strains of HIV and SHIV while bNAb concentration remains high. Vectored ImmunoProphylaxis (VIP) results in long-lived bNAb expression following a single intramuscular {IM) injection of a specialized vim\ vector, and this approach has been demonstrated as a means of durably suppressing viral load. However, previous reports of VIP-delivered bNAbs for HIV therapy required prior antiretroviral drug therapy to reduce viral load to prevent escape. Methods: Humanized BLT mice were infected IV with the REJO.c transmitted molecular founder strain ofHlV. A low dose of combination antiretroviral therapy (ART) was administered to these animals for 5 weeks, followed by a single h\f injection of VIP expressing VRC07 or luciferase. Mouse plasma was analyzed by ELISA to detennine antibody concentration and by qPCR to determine viral load. Cellular fractions were analyzed by flow cytometry to quantify human CD4 cells over time. After sacrifice, plasma was subjected to a clinically validated ultrasensitive PCR-based viral load assay. Results: We detected viral loads of 10 5 copies/mL in infected mice prior to low-dose ART treatment, which resulted in a transient reduction and rebound to pre-therapy loads. Following VIP administration, we observed a rapid increase in the blood concentration of VRC07. Mice expressing VRC07 exhibited a sharp decline in viral load to undetectable levels and an increase in CD4 cells over four weeks and this effect was sustained for the remaining S weeks of the study. In contrast, mice expressing luciferase exhibited increasing viral loads with concomitant decreases in CD4 cells throughout the study.
Conclusions Profectus Biosciences, Tarrytown, NY, United States Backgt'ound: Eliciting HIV-specific immune responses through vaccination remains an important goal in preventing HIV. Here we present safety, tolerability, and immunogenicity data from a phase fa trial of a novel HIV-I multi-antigen (MAG) DNA vaccine delivered by electroporation (EP) with DNA IL-12 adjuvant and boosted with an rVSV HIV-1 Gag vaccine. Methods: HVTN OS7 enrolled 100 healthy adults in a multicenter, randomized, double-blinded, placebo-controlled study.
Participants received 3,000mcg HIV-MAG (gag/pol, env, nef/ tat/vij) DNA vaccine co-administered with IL-12 DNA at 0, 250, 1000, or 1500mcg (N=22/group) or placebo (N=3/group) intramuscularly by EP at 0, 1 and 3 months boosted by rVSV Gag vaccine or placebo at 6 months. Participants were assessed for reactogenicity, tolerability, and adverse events. CD4 + and CDS+ T-cell responses to HIV potential T-cell epitope (PTE) peptides were measured by intracellular cytokine staining (ICS) 2 weeks after 3rd and 4th vaccinations. Results: EP was generally well tolerated. Local and systemic reactogenicity symptoms were generally mild to moderate. After the 4th vaccination some subjects experienced moderate to severe systemic symptoms and several experienced transient lyrnphopenia. After DNA prime, CD4+ T-cell responses to any PTE were detected in 77% of subjects and CDS+ T·cell re· sponses in 40%. Gag-specific CD4+ T-cell response rates after DNA prime increased significantly following rVSV Gag boost, from 15% to S6%. Gag-specific CDS+ T-cell responses also increased significantly from 6% after DNA prime to 26% after rVSV Gag boost. Backgrnund: GV-TH-01, a Phase 1 ope11-Jabel trial ofGOVXBll, a DNA/MVA prime-boost regimen, in HIV infected patients on ART was undertaken to evaluate safety and vaccineelicited T cell responses, and to explore viral rebound during analytical treatment interruption {TI). Methods: Patients who began ART within IS months of sero~ conversion and had sustained plasma HIV-I RNA<50 c/mL for at least 6 months were enrolled. Patients received a total of 4 inoculations at intervals of S weeks. 2 of pGA2/JS7 DNA (3mg) followed by 2 of MV A!HIV62B (I 0 8 TCID50). At 8 weeks after the last immunization, plus an efavirenz wash-out if needed, participants entered a TI phase of 12 weeks, after which ART was reinstituted. T cell responses were scored for IFNg or IL2 by flow cytometry following stimulation with Gag, Env and Pol peptides. Responses were considered positive if ~2-fold higher than pre-vaccination. Results: S of 9 men completed all vaccinations. For the S, median age was 37.5yrs, baseline CD4 count was 691/,uL (50!-1612/til) and all had HIV-I RNA <50 c/rnL. Median viral load prior to ART was 5.1 log!O c/mL (2.6·7.2 log!O c/mL). No serious adverse events occurred. After the 1' 1 or 2"d MV Al HIV62B immunization, Gag-specific CDS T cells were boosted over pre· vaccination levels in 7 out of S (P < 0.05) whereas Gagspecific CD4 T cells were boosted in 5 of S patients (P=0.2). 6 of S patients elicited previously undetectable CDS responses whereas 5 of S elicited previously undetectable CD4 responses to Gag epitopes. Gp120 or gp41-spccific antibody responses were boosted in 3 of S patient and 2 of 8 patients respectively. Excluding one acute seroconverter, the median reduction in HIV-1 RNA at weeks 2, 6, and 12 compared to pre-ART levels was -2.2, -1.3 and -0.8 loglO c/mL. Conclusions: This trial demonstrates the potential for GOVX-B 11 to boost both T cell and antibody responses in a therapeutic setting. A placebo-controlled trial will be required to further assess the therapeutic benefit of the \'accine.
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